Severity
of Brain Changes During Nicotine Withdrawal Comparable to Those for Other
Drugs of Abuse
Dramatic
changes in the brain's pleasure circuits during withdrawal from chronic
nicotine use rival the magnitude and duration of similar changes observed
during withdrawal from other
abused
drugs such as cocaine, opiates,amphetamines, and alcohol, according to
a new study funded by the NationalInstitute on Drug Abuse (NIDA), National
Institutes of Health. Scientists atThe Scripps Research Institute found
significant decreases in the sensitivityof the brains of laboratory rats
to pleasurable stimulation after nicotineadministration was abruptly stopped.
These changes
lasted several days, andmay correspond to the anxiety and depression experienced
by humans for several days after quitting smoking "cold turkey." "Understanding
these decreases in the brain's sensitivity to pleasurable stimulation that
occur during nicotine abstinence helps explain why it is so hard for people
to stop smoking. This understanding may
also help
in the development of better treatments to address the withdrawal symptoms
-
depression,
anxiety, irritability, and craving - that interfere with people's attempts
to quit
smoking,"
said Dr. Alan I. Leshner, director of NIDA. "The similarity to other drugs
of abuse emphasizes that there are common characteristics to withdrawal
from all addictive substances, one of which is a decrease in sensitivity
to pleasure."
A research
team led by Dr. Athina Markou of The Scripps Research Institute inLa Jolla,
California measured the effects of nicotine withdrawal and abstinence on
the brain's sensitivity to pleasurable electrical stimulation. Researchers
allowed rats to self-administer a baseline
intensity
of pleasurable electrical pulses and measured "pleasure" (or reward) associatedwith
stimulation of the area of the lateral hypothalamus, part of the brain'sreward
circuitry. Reward sensitivity measures were taken both during and afteradministration
of nicotine.
For one
week, the rats were given a steady dose of nicotine that produced blood
levels equivalent to those of an individual smoking one and a half packsof
cigarettes a day. While the nicotine was being administered, the rats'sensitivity
to brain reward remained stable, as indicated by no significantchange in
the self-administration of the electrical pulse. When the rats weretaken
off nicotine, however, intensities of electrical current had to beincreased
by more than 40 percent before the rats again found them to be pleasurable.
Brain reward sensitivity was affected for at least 4 days and some rats
did not return to baseline for over 2 weeks.
"These results
are comparable to the altered brain reward sensitivity found also during
withdrawal
from many other addictive drugs," said Dr. Markou. "The results of this
research indicate that we have a good animal model to study the neurobiology
of nicotine abstinence and thus assist in the development of behavioral
and pharmacological treatments for nicotine addiction." This research was
funded in part by Novartis Pharma AG of Basel, Switzerland. The study,
"Dramatic decreases in brain reward function during nicotinewithdrawal,"
will be
published
in the May 7 issue of NATURE.
The use
of nicotine products is a major preventable cause of death in the United
States. About
62 million
Americans age 12 and over are current cigarette smokers, making nicotine
one of
the most
heavily used addictive drugs. The scientific facts about nicotine addiction,
based on
the latest
research, will be the focus of Addicted to Nicotine: A National Research
Forum to be held July 27-28, 1998. The conference, sponsored by NIDA, the
Robert Wood Johnson
Foundation,
the National Cancer Institute, and the Centers for Disease Control and
Prevention's Office on Smoking and Health will highlight the sources of
nicotine addiction, prevention of tobacco product use, and state-of-the-art
treatment strategies. The conference will be held at
the Natcher
Auditorium on the NIH Campus in Bethesda, MD. For more information, contact
the NIDA Press Office.